Summary of clinical characteristics, treatment, and follow‐up information of all patients diagnosed with 
pneumonitis
PNEUMONITIS, DISEASE, DISEASE PROGRESSION
The information of all patients diagnosed with CIP is summarized in Table Summary information of all patients diagnosed with CIP.Abbreviation: CIP, checkpoint inhibitor‐related pneumonitis.Immunotherapy was restarted in 23 (38.3%) patients after treatment. The median time from the onset of CIP to the restart of immunotherapy was 51 days (range: 10–200 days). One patient developed CIP again at 70 days after the restart of immunotherapy and discontinued the ICI. Another patient died at 441 days after the immunotherapy restart due to the reoccurrence of CIP. As of July 30, 2022, 13 patients have experienced disease progression, and eight patients have stable disease and continue receiving immunotherapy (Figure Outcomes in patients who started immunotherapy rechallenge.